Market Cap 1.33B
Revenue (ttm) 2.55B
Net Income (ttm) -61.62M
EPS (ttm) N/A
PE Ratio 111.80
Forward PE 638.86
Profit Margin -2.41%
Debt to Equity Ratio 0.57
Volume 491,110
Avg Vol 2,627,100
Day's Range N/A - N/A
Shares Out 117.40M
Stochastic %K 42%
Beta 1.01
Analysts Strong Sell
Price Target $15.31

Company Profile

Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated platform for health plan administration and value-based business infrastructure. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system tha...

Industry: Health Information Services
Sector: Healthcare
Phone: 571 389 6000
Address:
1812 N. Moore Street, Suite 1705, Arlington, United States
TOMKiLA
TOMKiLA Jul. 14 at 2:06 PM
$EVH Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
0 · Reply
TOMKiLA
TOMKiLA Jul. 3 at 12:03 PM
$EVH finally after months of losses we are seeing a strong movement
0 · Reply
BPler
BPler Jul. 2 at 10:41 AM
My undervalued companies picks for Q3 runner $FNKO $EVH $GPRO $CRVO $CERO Banking om Cervomed, Cero Therapeutics and GoPro the most for a potential squeeze; Funko and EVH will just run up slowly
1 · Reply
Nnanok
Nnanok Jul. 2 at 8:27 AM
$EVH With more therapeutic choices based on "personalized medicine" (IE diagnostic biomarkers), trends towards orphan and DTT disease indications, AI efficiency apps both at the FDA and in the biotech industry, all bullish trends for EVH. Long EVH.
0 · Reply
JarvisFlow
JarvisFlow Jun. 30 at 12:00 PM
JMP Securities updates rating for Evolent Health ( $EVH ) to Market Outperform, target set at 18 → 12.
0 · Reply
TOMKiLA
TOMKiLA Jun. 26 at 12:37 PM
$EVH John Johnson, Evolent's Chief Financial Officer, noted, "We are pleased to see oncology trend remaining below forecast now for the first two thirds of the quarter. If these trends continue through June, we would anticipate being in the top half of our range for q2 ebtda ." The company also announced it signed a Commitment Letter with Ares Management Credit funds, securing the option to borrow additional non-dilutive capital, if needed, to address its 2025 Convertible Notes while leaving incremental working capital on its balance sheet to support Evolent's accelerating organic growth pipeline. Seth Blackley, Evolent's Chief Executive Officer, noted, "A recent acceleration in our business development activities has led us to significantly increase our forecast for new revenue bookings going into 2026. This option for incremental, non-dilutive capital availability ensures we can execute on any working capital needs associated with that higher growth forecast."
0 · Reply
Winning_calls
Winning_calls Jun. 25 at 11:32 PM
$EVH enjoy that members
0 · Reply
TOMKiLA
TOMKiLA Jun. 25 at 12:22 PM
$EVH now the margin are 19% so the gross profit should be $420M $ in 2025 The other costs (personal + depreciation + other costs ) should be between 350 and 450 m) so we are so close to see strong returns of investment between the third quarter 2025 to 4 quarter 2026! Probably evolent should increase revenues 20/25% with some good news and show strong increase or net margin
0 · Reply
Krazy4you
Krazy4you Jun. 25 at 1:24 AM
$EVH look like it’s getting close to a squeeze here. RSI is 69 on the daily. Should hit around 79-80 on daily before a reset. Needs to go over 11.56. 🍀
0 · Reply
Winning_calls
Winning_calls Jun. 24 at 7:19 PM
$EVH 💋😎😎
0 · Reply
Latest News on EVH
Evolent announces key appointments to leadership team

Jul 9, 2025, 8:00 AM EDT - 7 days ago

Evolent announces key appointments to leadership team


Evolent Health, Inc. (EVH) Q1 2025 Earnings Call Transcript

May 9, 2025, 6:03 PM EDT - 2 months ago

Evolent Health, Inc. (EVH) Q1 2025 Earnings Call Transcript


Evolent Announces First Quarter 2025 Results

May 8, 2025, 4:10 PM EDT - 2 months ago

Evolent Announces First Quarter 2025 Results


Evolent Health, Inc. (EVH) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 7:28 PM EST - 5 months ago

Evolent Health, Inc. (EVH) Q4 2024 Earnings Call Transcript


Evolent Announces Fourth Quarter and Full Year 2024 Results

Feb 20, 2025, 4:10 PM EST - 5 months ago

Evolent Announces Fourth Quarter and Full Year 2024 Results


Evolent Health Announces Changes to Board of Directors

Feb 4, 2025, 7:00 AM EST - 5 months ago

Evolent Health Announces Changes to Board of Directors


Evolent Health: A Shot At Revival After Market Bruising

Nov 12, 2024, 2:37 AM EST - 8 months ago

Evolent Health: A Shot At Revival After Market Bruising


Evolent Health, Inc. (EVH) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 9:12 AM EST - 8 months ago

Evolent Health, Inc. (EVH) Q3 2024 Earnings Call Transcript


Evolent Announces Third Quarter 2024 Results

Nov 7, 2024, 4:10 PM EST - 8 months ago

Evolent Announces Third Quarter 2024 Results


Evolent Health Inc (EVH) Stock Price Down 3.2% on Oct 2

Oct 2, 2024, 12:08 PM EDT - 10 months ago

Evolent Health Inc (EVH) Stock Price Down 3.2% on Oct 2


Evolent Health: Let The Bidding Begin

Aug 23, 2024, 9:00 AM EDT - 11 months ago

Evolent Health: Let The Bidding Begin


Evolent Health, Inc. (EVH) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 9:18 PM EDT - 1 year ago

Evolent Health, Inc. (EVH) Q2 2024 Earnings Call Transcript


Evolent Announces Second Quarter 2024 Results

Aug 8, 2024, 4:10 PM EDT - 1 year ago

Evolent Announces Second Quarter 2024 Results


Evolent Announces First Quarter 2024 Results

May 9, 2024, 4:10 PM EDT - 1 year ago

Evolent Announces First Quarter 2024 Results


Evolent Health, Inc. (EVH) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 10:34 PM EST - 1 year ago

Evolent Health, Inc. (EVH) Q4 2023 Earnings Call Transcript


Evolent Announces Fourth Quarter and Full Year 2023 Results

Feb 22, 2024, 4:10 PM EST - 1 year ago

Evolent Announces Fourth Quarter and Full Year 2023 Results


Evolent Health, Inc. (EVH) Q3 2023 Earnings Call Transcript

Nov 4, 2023, 3:13 AM EDT - 1 year ago

Evolent Health, Inc. (EVH) Q3 2023 Earnings Call Transcript


Evolent Announces Third Quarter 2023 Results

Nov 2, 2023, 4:10 PM EDT - 1 year ago

Evolent Announces Third Quarter 2023 Results


A First Evaluation On Evolent Health

Oct 4, 2023, 3:16 PM EDT - 1 year ago

A First Evaluation On Evolent Health


Evolent Health to Participate in Upcoming Conferences

Aug 8, 2023, 5:00 PM EDT - 2 years ago

Evolent Health to Participate in Upcoming Conferences


Evolent Health, Inc. (EVH) Q2 2023 Earnings Call Transcript

Aug 2, 2023, 11:25 PM EDT - 2 years ago

Evolent Health, Inc. (EVH) Q2 2023 Earnings Call Transcript


Evolent Announces Second Quarter 2023 Results

Aug 2, 2023, 4:10 PM EDT - 2 years ago

Evolent Announces Second Quarter 2023 Results


Evolent welcomes Toyin Ajayi to its Board of Directors

Jul 26, 2023, 4:42 PM EDT - 2 years ago

Evolent welcomes Toyin Ajayi to its Board of Directors


Evolent Health, Inc. (EVH) Q1 2023 Earnings Call Transcript

May 3, 2023, 10:50 PM EDT - 2 years ago

Evolent Health, Inc. (EVH) Q1 2023 Earnings Call Transcript


Evolent Health Announces First Quarter 2023 Results

May 3, 2023, 4:10 PM EDT - 2 years ago

Evolent Health Announces First Quarter 2023 Results


TOMKiLA
TOMKiLA Jul. 14 at 2:06 PM
$EVH Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
0 · Reply
TOMKiLA
TOMKiLA Jul. 3 at 12:03 PM
$EVH finally after months of losses we are seeing a strong movement
0 · Reply
BPler
BPler Jul. 2 at 10:41 AM
My undervalued companies picks for Q3 runner $FNKO $EVH $GPRO $CRVO $CERO Banking om Cervomed, Cero Therapeutics and GoPro the most for a potential squeeze; Funko and EVH will just run up slowly
1 · Reply
Nnanok
Nnanok Jul. 2 at 8:27 AM
$EVH With more therapeutic choices based on "personalized medicine" (IE diagnostic biomarkers), trends towards orphan and DTT disease indications, AI efficiency apps both at the FDA and in the biotech industry, all bullish trends for EVH. Long EVH.
0 · Reply
JarvisFlow
JarvisFlow Jun. 30 at 12:00 PM
JMP Securities updates rating for Evolent Health ( $EVH ) to Market Outperform, target set at 18 → 12.
0 · Reply
TOMKiLA
TOMKiLA Jun. 26 at 12:37 PM
$EVH John Johnson, Evolent's Chief Financial Officer, noted, "We are pleased to see oncology trend remaining below forecast now for the first two thirds of the quarter. If these trends continue through June, we would anticipate being in the top half of our range for q2 ebtda ." The company also announced it signed a Commitment Letter with Ares Management Credit funds, securing the option to borrow additional non-dilutive capital, if needed, to address its 2025 Convertible Notes while leaving incremental working capital on its balance sheet to support Evolent's accelerating organic growth pipeline. Seth Blackley, Evolent's Chief Executive Officer, noted, "A recent acceleration in our business development activities has led us to significantly increase our forecast for new revenue bookings going into 2026. This option for incremental, non-dilutive capital availability ensures we can execute on any working capital needs associated with that higher growth forecast."
0 · Reply
Winning_calls
Winning_calls Jun. 25 at 11:32 PM
$EVH enjoy that members
0 · Reply
TOMKiLA
TOMKiLA Jun. 25 at 12:22 PM
$EVH now the margin are 19% so the gross profit should be $420M $ in 2025 The other costs (personal + depreciation + other costs ) should be between 350 and 450 m) so we are so close to see strong returns of investment between the third quarter 2025 to 4 quarter 2026! Probably evolent should increase revenues 20/25% with some good news and show strong increase or net margin
0 · Reply
Krazy4you
Krazy4you Jun. 25 at 1:24 AM
$EVH look like it’s getting close to a squeeze here. RSI is 69 on the daily. Should hit around 79-80 on daily before a reset. Needs to go over 11.56. 🍀
0 · Reply
Winning_calls
Winning_calls Jun. 24 at 7:19 PM
$EVH 💋😎😎
0 · Reply
GSP
GSP Jun. 24 at 12:57 PM
1 · Reply
TOMKiLA
TOMKiLA Jun. 24 at 9:27 AM
$EVH after months of insane short selling now all feel positive for the market! Clown! Glad this company worth more 3 times than actual value but we need to wait 1 or 2 years to see a lot of results. 15$ first step within 5 months 19$ second step within 9 months 24$ third step within 18 months 30$ the last step within 2 years I can see profits next year (2026) with 18/22% revenues growth and net profits between 3 and 5% of all revenues Probably they need to see strong increase of gross profits
0 · Reply
Winning_calls
Winning_calls Jun. 23 at 2:46 PM
$EVH 😘😘
0 · Reply
Winning_calls
Winning_calls Jun. 23 at 1:56 PM
$EVH atta boy👊👊
0 · Reply
Winning_calls
Winning_calls Jun. 23 at 4:16 AM
$EVH pick me up @ $9.30
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 23 at 2:26 AM
UBS Views Evolent Health’s Q2 Outlook And Financing Moves As ‘Incrementally Positive’ $EVH https://stocktwits.com/news/equity/markets/ubs-views-evolent-health-s-q2-outlook-and-financing-moves-as-incrementally-positive/chmP8R8RR5P
0 · Reply
DonCorleone77
DonCorleone77 Jun. 22 at 8:27 PM
$EVH Evolent Health news Friday 'incrementally positive,' says UBS UBS says Evolent Health on Monday issued a press release that is "incrementally positive." The company issued a confirmation that oncology cost trends remain below expectations, a new debt commitment from Ares, a reiteration of its adjusted EBITDA guidance for Q2 and 2025, new debt financing to address 2025 convertibles, and also flagged a pickup in late-stage pipeline activity, the analyst tells investors in a research note. UBS believes that despite a solid Q1, Evolent shares are down 9% since April, largely on concerns that oncology cost trends remain elevated due.
0 · Reply
BPler
BPler Jun. 20 at 5:50 PM
$EVH 52W High was 33.63 USD, their is room for a squeeze up :)
0 · Reply
TOMKiLA
TOMKiLA Jun. 20 at 5:22 PM
$EVH 15$ after third quarter 2025
0 · Reply
BPler
BPler Jun. 20 at 12:53 PM
$CERO $CRVO $EVH $VFF https://www.youtube.com/shorts/wVHG3q6fcGw
0 · Reply
DonCorleone77
DonCorleone77 Jun. 20 at 10:39 AM
$EVH Evolent Health backs Q2 adjusted EBITDA view $33M-$40M Backs FY25 adjusted EBITDA view $135M-$156MEVOLENT Health announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 Adjusted EBITDA guidance of $33M-$40M and its full year Adjusted EBITDA guidance of $135M-$165M. John Johnson, Evolent's CFO, noted, "We are pleased to see oncology trend remaining below forecast now for the first two thirds of the quarter. We remain confident in meeting or beating the expectations we set for the 2nd quarter and full year. If these trends continue through June, we would anticipate being in the top half of our range for Q2 Adjusted EBITDA." The company also announced it signed a commitment letter with Ares Management Credit funds, securing the option to borrow additional non-dilutive capital, if needed, to address its 2025 Convertible Notes while leaving incremental working capital on its balance sheet to support Evolent's accelerating organic growth pipeline.
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 20 at 10:32 AM
Evolent ($EVH) doubles down on growth while maintaining financial discipline. Reiterates Q2/FY25 EBITDA guidance with oncology costs trending below expectations. Secured non-dilutive financing from Ares to support accelerating 2026 bookings pipeline. Balance sheet flexibility meets growth ambition - rare combo in healthcare tech. https://www.prnewswire.com/news-releases/evolent-reiterates-q2-and-full-year-guidance-for-adjusted-ebitda-302486700.html
0 · Reply